Efficacy of intravenous aspirin use in patients with acute coronary syndrome.
- Author:
Yan ZHAO
1
;
Lu-Hua SHEN
;
Ming YANG
Author Information
- Publication Type:Journal Article
- MeSH: Acute Coronary Syndrome; drug therapy; Administration, Oral; Adult; Aged; Aged, 80 and over; Angina, Unstable; drug therapy; Aspirin; administration & dosage; Feasibility Studies; Female; Humans; Injections, Intravenous; Male; Middle Aged; Myocardial Infarction; drug therapy
- From: Chinese Journal of Cardiology 2007;35(12):1126-1129
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo compare the efficacy of intravenous versus oral aspirin use in patients with acute coronary syndrome (ACS).
METHODSACS patients were randomly treated with intravenous aspirin (300 mg/d, IA, n = 30), low oral aspirin (100 mg/d, OA1, n = 32) or high oral aspirin (300 mg/d, OA2, n = 33). Aspirin sensitivity was tested by optical platelet aggregation using adenosine diphosphate (ADP) and arachidonic acid (AA). The serum CD62p contents were examined by Flow cytometry.
RESULTSPlatelet aggregation expressed as ratio of reduction of ADP and AA post various aspirin were similar among 3 groups [IA: ADP (12.0 +/- 10.4)%, AA (6.7 +/- 11.2)%; OA1: ADP (6.0 +/- 14.6)%, AA (6.9 +/- 12.3)%; OA2: ADP (9.4 +/- 16.6)%, AA (7.3 +/- 13.0)%, all P > 0.05]. CD62p decreasing level post various aspirin were also similar among groups [IA: (10.9 +/- 18.6)%, OA1: (9.0 +/- 11.8)%, OA2: (7.1 +/- 15.7)%, all P > 0.05]. Side-effects and MACE post various aspirin use were comparable among groups.
CONCLUSIONInhibiting efficacy on platelets function by intravenous aspirin (300 mg/d) was comparable to that of by oral aspirin (100 mg/d, 300 mg/d) in patients with acute coronary syndrome and could be used as an alternative route for patients who can't take oral aspirin.
